Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2017 vs Humira in moderate to severe chronic plaque psoriasis
2013-000747-11Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in psoriasis (2 arms), sponsored by Hexal AG. Primary endpoint: PASI 75 response rate at Week 16. Started Sep 2013; status: completed.
02
Drugs
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2013-000747-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000747-11.